Botanical species · safety record

Oenothera biennis

The EFSA Compendium of Botanicals holds 1 constituent measurement and 2 adverse-effect records for Oenothera biennis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Oenothera biennis L.

1Constituent measurements
2Safety records
3Cited sources
631Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 631 licensed products naming Oenothera biennis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry

Source material stated

  • Bark (trunk)
  • Grain(s)
  • Graine
  • Leaf
  • New material
  • Oenothera biennis - Seed
  • Oenothera biennis - Seed Oil
  • Plante entière

What the records describe

Constituents measured

  • Ellagitannins (hydrolysable tannins)1

Plant parts

  • Live plants1
  • Seed1
  • Unspecified1

Preparations

  • Solvent extraction2
  • Essential oil (as part-nature)1

Effect types

  • Digestive1
  • Hemopoietic1

Target tissues

  • Blood coagulation1
  • Digestive1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
Ellagitannins (hydrolysable tannins)Live plantsSolvent extractionHPLC-DADResolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveDigestiveSeedSolvent extractionIn vitroNo resolvable identifier
HemopoieticBlood coagulationUnspecifiedEssential oil (as part-nature)Case reportNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Jacobsson, Ingela., Joensson, Anna K., Gerden, Barbro., Haegg, Staffan. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiology and drug safety, 2009, p. 1039-1047.
  2. Aitani, M., Kimura, H., Abiru, Y., Soyama, H., Murakami, H., Zhang, HL., Sugishita, T., Konishi, Y. Effect of an extract from evening-primrose seeds on postprandial blood glucose level and its active components . Journal of the japanese society for food science and technology-nippon shokuhin kagaku kogaku kaishi, 2003, vol. 50, no. 4, p. 180-187.
  3. Karonen, Maarit., Parker, John., Agrawal, Anurag., Salminen, Juha-Pekka. First evidence of hexameric and heptameric ellagitannins in plants detected by liquid chromatography/electrospray ionisation mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2010, vol. 24, no. 21, p. 3151-3156. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue